Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 9, 2013, Pages 1381-1386

  Russell, James A ^a   Kangarloo, Shahbal B ^a   Williamson, Tyler ^b   Chaudhry, M Ahsan ^a   Savoie, Mary Lynn ^a   Turner, A Robert ^c   Larratt, Loree ^c   Storek, Jan ^a   Bahlis, Nizar J ^a   Shafey, Mona ^a   Brown, Christopher B ^a   Yang, Maggie ^a   Geddes, Michelle ^a   Zacarias, Nancy ^a   Yue, Ping ^a   Duggan, Peter ^a   Stewart, Douglas A ^a   Daly, Andrew ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

Busulfan; Exposure; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIBODY; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; WALDENSTROEM MACROGLOBULINEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84882747340     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.07.002     Document Type: Article

References (26)

1. Russell J.A., Kangarloo S.B. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008, 14:1936-1949.
2. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007, 13:814-821.
3. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
4. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched-pair analysis. Biol Blood Marrow Transplant 2007, 13:299-306.
5. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
6. Alatrash G., de Lima M., Hamerschlak N., et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011, 17:1490-1496.
7. Andersson B.S., de Lima M., Thall P.F., et al. Once-daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
8. Perkins J.B., Kim J., Anasetti C., et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1099-1107.
9. Pidala J., Kim J., Anasetti C., et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. JHematol Oncol 2010, 3:36.
10. + lymphoid malignancies without increased risk of infectious complications. Int J Hematol 2011, 93:206-212.
11. Santarone S., Pidala J., Di Nicola M., et al. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Transplant 2011, 17:1505-1511.
12. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.
13. Daly A., Savoie M.L., Geddes M., et al. Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities. Biol Blood Marrow Transplant 2012, 18:1921-1926.
14. Russell J.A., Irish W., Balogh A., et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant 2010, 16:509-514.
15. Russell J.A., Chaudhry A., Booth K., et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 2000, 6:109-114.
16. Kangarloo S.B., Naveed F., Ng E.S., et al. Development and validation ofatest dose strategy for once-daily i.v. busulfan: importance of fixedinfusion rate dosing. Biol Blood Marrow Transplant 2012, 18:295-301.
17. Barrett J. Graft-versus-host disease. Bone marrow transplantation in practice 1992, 257. Churchill Livingstone, Edinburgh (UK). J. Treleaven, J. Barrett (Eds.).
18. Fine J.P., Gray R.J. Aproportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999, 94:496-509.
19. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
20. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:31-42.
21. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996, 17:225-230.
22. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
23. Ferrara J.L., Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006, 43:3-10.
24. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
25. Lewis V., Naveed F., Kangarloo S., et al. Influence of busulfan exposure on allogeneic transplant outcome using a fludarabine/busulfan/thymoglobulin/total body irradiation preparative regimen for adult acute myelogenous leukaemia. Bone Marrow Transplant 2010, 45:s83.
26. Andersson B.S., de Lima M.J., Saliba R.M., et al. Pharmacokinetic dose guidance of IV busulfan with fludarabine with allogeneic stem cell transplantation improves progression free survival in patients with AML and MDS; results of a randomized phase III study. Blood 2011, 118:892.